Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
Graviton BioScience Corporation announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101, enabling the initiation of a Phase 2 clinical study in individuals living with FA. Enrollment is expected to begin in the first quarter of 2027.
